ConductScience.org, home

Paper2553992

Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.

Tan KB and 4 others. J Natl Cancer Inst, 1989. Cited by 188 papers, by iCite.

Cite this record

ConductScience Library. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. Papers, record 2553992. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2553992

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
PubMed
Journal
J Natl Cancer Inst
PubMed
Year
1989
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
188
iCite
Relative citation ratio, by iCite
5.14
iCite
Revised in PubMed
2019-05-10
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tan KBK B
2Mattern MRM R
3Eng WKW K
4McCabe FLF L
5Johnson RKR K

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AmsacrineMajor topic
CamptothecinMajor topic
DNA Topoisomerases, Type IMajor topic
DNA Topoisomerases, Type IIMajor topic
Gene RearrangementMajor topic
Leukemia P388Major topic
Leukemia, ExperimentalMajor topic
Alleles
Animals
Drug Resistance
Gene Expression Regulation
Methylation
Methyltransferases
Mice
RNA, Messenger
Topoisomerase I Inhibitors
Topoisomerase II Inhibitors
Transcription, Genetic

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
CA-40884NCI NIH HHSUnited StatesPubMed

Source PubMed

Download CSV of grants

Cited by29

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 188 citations.

PMIDTitleJournalYearIn PapersSource
36408699Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).Thorac Cancer2023https://conductscience.org/library/papers/36408699PubMed
36248326Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study.Transl Lung Cancer Res2022https://conductscience.org/library/papers/36248326PubMed
35740594Drug Resistance in Colorectal Cancer: From Mechanism to Clinic.Cancers (Basel)2022https://conductscience.org/library/papers/35740594PubMed
28454315Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer.Oncol Lett2017https://conductscience.org/library/papers/28454315PubMed
26270258Nanodrug Formed by Coassembly of Dual Anticancer Drugs to Inhibit Cancer Cell Drug Resistance.ACS Appl Mater Interfaces2015https://conductscience.org/library/papers/26270258PubMed
26199623Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma.Gastroenterol Res Pract2015https://conductscience.org/library/papers/26199623PubMed
24875756Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs.Biomaterials2014https://conductscience.org/library/papers/24875756PubMed
23215027
Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Mol Pharm2013https://conductscience.org/library/papers/23215027PubMed
22966396Methylated BNIP3 gene in colorectal cancer prognosis.Oncol Lett2010https://conductscience.org/library/papers/22966396PubMed
21159664Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.Cancer Res2011https://conductscience.org/library/papers/21159664PubMed
21069340Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.Cancer Chemother Pharmacol2011https://conductscience.org/library/papers/21069340PubMed
19332675
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
Antimicrob Agents Chemother2009https://conductscience.org/library/papers/19332675PubMed
17984197Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.Mol Pharmacol2008https://conductscience.org/library/papers/17984197PubMed
17479288Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.J Cancer Res Clin Oncol2007https://conductscience.org/library/papers/17479288PubMed
15793124Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani.Antimicrob Agents Chemother2005https://conductscience.org/library/papers/15793124PubMed
12743815Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin.Virchows Arch2003https://conductscience.org/library/papers/12743815PubMed
11592782Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants.Br J Cancer2001https://conductscience.org/library/papers/11592782PubMed
10604726Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines.Br J Cancer1999https://conductscience.org/library/papers/10604726PubMed
9414662Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.Jpn J Cancer Res1997https://conductscience.org/library/papers/9414662PubMed
9400949Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.Br J Cancer1997https://conductscience.org/library/papers/9400949PubMed

See all 29 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2553992

GET https://conductscience.org/api/papers/v1/2553992/cited_by?page=2